What is Neurocrine Biosciences?
Neurocrine Biosciences is a neuroscience-focused biopharmaceuticals company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Neuroscience-focused biopharmaceuticals
- Headquarters
- San Diego, CA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: NBIX
What is Neurocrine Biosciences?
Neurocrine Biosciences is a neuroscience-focused biopharmaceuticals company headquartered in San Diego, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Neurocrine Biosciences is a neuroscience-focused biopharmaceuticals company headquartered in San Diego, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Neurocrine Biosciences should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Neurocrine Biosciences offer?
Neurocrine Biosciences's profile centers on INGREZZA, Movement disorder therapies, Neuroendocrinology, Psychiatry pipeline.
- INGREZZA· Neuroscience-focused biopharmaceuticals
- Movement disorder therapies· Neuroscience-focused biopharmaceuticals
- Neuroendocrinology· Neuroscience-focused biopharmaceuticals
- Psychiatry pipeline· Neuroscience-focused biopharmaceuticals
- Clinical development· Neuroscience-focused biopharmaceuticals
- Commercial neurology· Neuroscience-focused biopharmaceuticals
How does Neurocrine Biosciences make money?
Neurocrine Biosciences makes money through commercial activity tied to neuroscience-focused biopharmaceuticals.
Neurocrine Biosciences monetizes through the model common to neuroscience-focused biopharmaceuticals: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Neurocrine Biosciences?
Neurocrine Biosciences's named executives should be verified on the official leadership or investor-relations page before outreach.
- Neurocrine Biosciences executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Neurocrine Biosciences finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Neurocrine Biosciences operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Neurocrine Biosciences's leadership?
Neurocrine Biosciences should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.neurocrine.com- Neurocrine Biosciences investor relationsInvestor relations / corporate contactcontact via https://www.neurocrine.com
- Neurocrine Biosciences sales or partnershipsCommercial contact routecontact via https://www.neurocrine.com
- Neurocrine Biosciences media relationsMedia or communications contact routecontact via https://www.neurocrine.com
How is Neurocrine Biosciences funded?
Neurocrine Biosciences's current status is Public company; Nasdaq: NBIX.
Neurocrine Biosciences's capital profile is best understood through its current public-company status: Public company; Nasdaq: NBIX. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Neurocrine Biosciences get here?
Neurocrine Biosciences's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingNeurocrine Biosciences is foundedThe company begins building in neuroscience-focused biopharmaceuticals.
- Scale-upCommercial footprint expandsNeurocrine Biosciences broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: NBIXPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Neurocrine Biosciences's competitors?
Neurocrine Biosciences competes with larger incumbents and focused specialists in neuroscience-focused biopharmaceuticals.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Neurocrine Biosciences — frequently asked questions
